Gland Pharma (NSE:GLAND) Accounts Payable & Accrued Expense : ₹9,143 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Gland Pharma Accounts Payable & Accrued Expense?

Gland Pharma's quarterly accounts payable & accrued expense declined from Sep. 2023 (₹10,397 Mil) to Dec. 2023 (₹0 Mil) but then increased from Dec. 2023 (₹0 Mil) to Mar. 2024 (₹9,143 Mil).

Gland Pharma's annual accounts payable & accrued expense increased from Mar. 2022 (₹5,190 Mil) to Mar. 2023 (₹6,175 Mil) and increased from Mar. 2023 (₹6,175 Mil) to Mar. 2024 (₹9,143 Mil).

Gland Pharma Accounts Payable & Accrued Expense Historical Data

The historical data trend for Gland Pharma's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gland Pharma Accounts Payable & Accrued Expense Chart

Gland Pharma Annual Data

Trend

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

2,962.96

4,484.76

5,190.17

6,174.86

9,143.29

Gland Pharma Quarterly Data
	Mar19	Jun19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															6,174.86	-	10,397.42	-	9,143.29

Gland Pharma Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Gland Pharma (NSE:GLAND) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gland Pharma Ltd (NSE:GLAND) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

543245:India

Address

Plot No. 11 and 84, TSIIC Phase: IV, Pashamylaram (V), Patancheru (M), Sangareddy District, Hyderabad, TG, IND, 502307

Website

https://www.glandpharma.com

Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. Further, the group is involved in vast range of therapeutic categories that include Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarial, Cardiology and more - to Hormones and related Drugs, Fertility Supplements and Gnrh Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA.

Gland Pharma (NSE:GLAND) Headlines

No Headlines